Perioperative hypertensive crisis: Newer concepts

International Anesthesiology Clinics

Volumn 50, Issue 2, 2012, Pages 40-58

  Fontes, Manuel L ^a   Varon, Joseph ^b,c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLEVIDIPINE; CLONIDINE; COCAINE; DEXMEDETOMIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRILAT; ESMOLOL; FENOLDOPAM; GLYCERYL TRINITRATE; HYDRALAZINE; LABETALOL; NICARDIPINE; NITROPRUSSIDE SODIUM; OPIATE; PLACEBO;

ACUTE POSTOPERATIVE HYPERTENSION; ANESTHESIA INDUCTION; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLONIDINE WITHDRAWAL SYNDROME; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EMERGENCY CARE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART STROKE VOLUME; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INTRAOPERATIVE PERIOD; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG EDEMA; MORTALITY; OSCILLOMETRY; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPEATED DRUG DOSE; REVIEW; RISK FACTOR; SYMPATHECTOMY; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; TREATMENT OUTCOME; VASODILATATION; WITHDRAWAL SYNDROME;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; PERIOPERATIVE CARE;

EID: 84859629010     PISSN: 00205907     EISSN: 15371913     Source Type: Journal    
DOI: 10.1097/AIA.0b013e31825430fd     Document Type: Review

References (132)

1. Rosamond W, Flegal K, Friday G, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.
2. Leslie JB. Incidence and aetiology of perioperative hypertension. Acta Anaesthesiol Scand Suppl. 1993;99:5-9. (Pubitemid 23114987)
3. Kaplan NM. New issues in the treatment of isolated systolic hypertension. Circulation. 2000;102:1079-1081.
4. van den Born BJ, Koopmans RP, Groeneveld JO, et al. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens. 2006;24:2299-2304. (Pubitemid 44611041)
5. [WHO] World Health Organization. 2002. http://www.who.int/whr/2010/whr10- en.pdf.
6. The JNC VII Report. Natural history of hypertension subtypes. Circulation. 2003;111:1094-1096.
7. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA. 2003;289:2560-2571.
8. The sixth report of the Joint National Committee on prevention, detection, evaluations and treatment of high blood pressure. Arch Intern Med. 1997;157: 2413-2446.
9. Rutan GH, McDonald RH, Kuller LH. A historical perspective of elevated systolic vs diastolic blood pressure from an epidemiological and clinical trial viewpoint. J Clin Epidemiol. 1989;42:663-673. (Pubitemid 19190647)
10. Baker G, Page L, Leadbetter G. Hypertension and renovascular disease - a followup study of 23 patients, with an analysis of factors influencing the results of surgery. N Engl J Med. 1962;267:1325-1334.
11. Prys-Roberts C, Greene LT, Meloch R, et al. Studies of anaesthesia in relation to hypertension. II. Hemodynamics consequences of induction and endotracheal intubation. Br J Anaesth. 1971;42:531-547.
12. Prys-Roberts C. Anaesthesia and hypertension. Br M Anaesth. 1984;56:711-724.
13. Goldman L, Caldera DL. Risks of general anesthesia and elective operation in the hypertensive patient. Anesthesiology. 1979;50:285-292. (Pubitemid 9161587)
14. Khuri SF, Daley J, Henderson W, et al. The National Veterans administration surgical risk study: risk adjustment for the comparative assessment of the quality of surgical care. J Am Coll Surg. 1995;180:519-531.
15. Aronson S, Boisvert D, Lapp W. Isolated systolic hypertension is associated with adverse outcomes from coronary artery bypass grafting surgery. Anesth Analg. 2002;94: 1079-1084. (Pubitemid 34441812)
16. Aronson S, Fontes ML, Miao Y, et al. Investigators of the Multicenter Study of Perioperative Ischemia Research Group. Ischemia Research and Education Foundation. Risk index for perioperative renal dysfunction/failure: critical dependence on pulse pressure hypertension. Circulation. 2007;115:733-742.
17. Howell SJ, Sear YM, Yeates D, et al. Hypertension, admission blood pressure and perioperative cardiovascular risk. Anaesthesia. 1996;51:1000-1004. (Pubitemid 26377176)
18. Rose DK, Cohen MM, DeBoer DP. Cardiovascular events in the postanesthesia care unit: contribution of risk factors. Anesthesiology. 1996;84:772-781. (Pubitemid 26105239)
19. Mangano DT, Browner WS, Hollenberg M, et al. The Study of Perioperative Ischemia Research Group. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. N Engl J Med. 1990;323:1781-1788.
20. Stone JG, Föex P, Sear JW, et al. Risk of myocardial ischaemia during anaesthesia in treated and untreated hypertensive patients. Br J Anaesth. 1988;61:675-679. (Pubitemid 19006340)
21. Mauney FM Jr, Ebert PA, Sabiston DC Jr. Postoperative myocardial infarction: a study of predisposing factors, diagnosis and mortality in a high risk group of surgical patients. Ann Surg. 1970;172:497-503.
22. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:199-206. (Pubitemid 37430058)
23. Cutler JA. High blood pressure and end-organ damage. J Hypertens. 1996; 14:53-56.
24. Fontes ML, Aronson S, Mathew JP, et al. for the Multicenter Study of Perioperative Ischemia (McSPI) Research Group*and the Ischemia Research and Education Foundation (IREF) Investigators. Risk of adverse outcome in coronary bypass surgery. Anesth Analg. 2008;107:1123-1130.
25. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney. Hypertension. 2005;46:200-204. (Pubitemid 40946514)
26. Safer ME, Levy BI, Struijker-Boudier H. Current perspective on arterial stiffness and pulse pressure in hypertension and cardiovascular disease. Circulation. 2003;107:2864-2869. (Pubitemid 36705999)
27. Wilkinson IB, Cockcroft JR. Mind the gap: pulse pressure, cardiovascular risk, and isolated systolic hypertension. Am J Hypertens. 2000;13:1315-1317.
28. Vaccarino V, Holford TR, Krumholz HM. Pulse pressure and risk for myocardial infarction and heart failure in the elderly. J Am Coll Cardiol. 2000;36:130-138. (Pubitemid 30466123)
29. Benetos A, Rudnichi A, Safar M, et al. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension. 1998;32:560-564. (Pubitemid 28429149)
30. Staessen JA, Gasowski J, Wang Ji, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet. 2000;355:865-872. (Pubitemid 30137665)
31. Klassen PS, Lowrie EG, Reddan DN, et al. Association between pulse pressure and mortality inpatients undergoing maintenance hemodialysis. JAMA. 2002;287:1548-1555. (Pubitemid 34270000)
32. Tosawa M, Iseki K, Iseki C, et al. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int. 2002;61:717-726. (Pubitemid 34102615)
33. Domanski MJ, Davis BR, Pfeifer MA, et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension. 1999;34:375-380. (Pubitemid 29426749)
34. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation. 1999;100:353-360.
35. Charlson ME, MacKenzie CR, Gold JP, et al. Intraoperative blood pressure. What patterns identify patients at risk for postoperative complications? Ann Surg. 1990; 212:567-580.
36. Reich DL, Bennett-Guerrero E, Bodian CA, et al. Intraoperative tachycardia and hypertension are independently associated with adverse outcome in noncardiac surgery of long duration. Anesth Analg. 2002;95:273-277. (Pubitemid 34793082)
37. Haas CE, LeBlanc JM. Acute postoperative hypertension: a review of therapeutic options. Am J Health Syst Pharm. 2004;61:1661-1673.
38. Basali A, Mascha EJ, Kalfas I, et al. Relation between perioperative hypertension and intracranial hemorrhage after craniotomy. Anesthesiology. 2000;93:48-54. (Pubitemid 30436676)
39. Mangano DT. Cardiovascular morbidity and CABG surgery- a perspective: epidemiology, costs, and potential therapeutic solutions. J Card Surg. 1995;10:366-368.
40. Wallach R, Karp RB, Reves JG, et al. Pathogenesis of paroxysmal hypertension developing during and after coronary bypass surgery: a study of hemodynamic and humoral factors. Am J Cardiol. 1980;46:559-565. (Pubitemid 10009807)
41. Hines R, Barash PG,Watrous G, et al. Complications occurring in the postanesthesia care unit: a survey. Anesth Analg. 1992;74:503-509.
42. Moller JT, Johannessen NW, Espersen K, et al. Randomized evaluation of pulse oximetry in 20,802 patients: II. Perioperative events and postoperative complications. Anesthesiology. 1993;78:445-453.
43. Weant KA, Flynn JD, Smith KM. Postoperative hypertension. Orthopedics. 2004;27: 1159-1161. (Pubitemid 39549588)
44. Houston MC. Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome. Am Heart J. 1981;102:(3 Pt 1):415-430. (Pubitemid 11018844)
45. O'Connor DE. Accelerated acute clonidine withdrawal syndrome during coronary artery bypass surgery. A case report. Br J Anaesth. 1981;53:431-433. (Pubitemid 11112188)
46. Berge KH, Lanier WL. Myocardial infarction accompanying acute clonidine withdrawal in a patient without a history of ischemic coronary artery disease. Anesth Analg. 1991;72:259-261.
47. Neusy AJ, Lowenstein J. Blood pressure and blood pressure variability following withdrawal of propranolol and clonidine. J Clin Pharmacol. 1989;29:18-24. (Pubitemid 19058234)
48. Bussmann WD, Kenedi P, von Mengden HJ, et al. Comparison of nitroglycerin with nifedipine in patients with hypertensive crisis or severe hypertension. Clin Investig. 1992;70:1085-1088.
49. Estafanous FG. Hypertension in the surgical patient: management of blood pressure and anesthesia. Cleve Clin J Med. 1989;56:385-393. (Pubitemid 20121590)
50. Shepherd AM, Ludden TM, McNay JL, et al. Hydralazine kinetics after single and repeated oral doses. Clin Pharmacol Ther. 1980;28:804-811. (Pubitemid 11213117)
51. Shepherd AM, Irvine NA. Differential hemodynamic and sympathoadrenal effects of sodium nitroprusside and hydralazine in hypertensive subjects. J Cardiovasc Pharmacol. 1986;8:527-533. (Pubitemid 16034815)
52. Powers DR, Papadakos PJ, Wallin JD. Parenteral hydralazine revisited. J Emerg Med. 1998;16:191-196. (Pubitemid 28169854)
53. Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: metaanalysis. BMJ. 2003;327:955-960. (Pubitemid 37330398)
54. Marik PE, Varon J. Hypertensive crises: challenges and management. Chest. 2007;131:1949-1962. (Pubitemid 46981658)
55. Mann T, Cohn PF, Holman LB, et al. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation. 1978;57:732-738.
56. Cohn JN, Franciosa JA, Francis GS, et al. Effect of short-term infusion of sodium nitroprusside on mortality rate in acute myocardial infarction complicated by left ventricular failure: results of a Veterans Administration cooperative study. N Engl J Med. 1982;306:1129-1135. (Pubitemid 12161335)
57. Elliott WJ, Weber RR, Nelson KS, et al. Renal and hemodynamic effects of intravenous fenoldopam versus nitroprusside in severe hypertension. Circulation. 1990;81:970-977. (Pubitemid 20090395)
58. Hartmann A,Buttinger C, Rommel T, et al. Alteration of intracranial pressure, cerebral blood flow, autoregulation and carbondioxide-reactivity by hypotensive agents in baboons with intracranial hypertension. Neurochirurgia (Stuttg). 1989;32:37-43. (Pubitemid 19089362)
59. Kondo T, Brock M, Bach H. Effect of intra-arterial sodium nitroprusside on intracranial pressure and cerebral autoregulation. Jpn Heart J. 1984;25:231-237. (Pubitemid 14132585)
60. Griswold WR, Reznik V, Mendoza SA. Nitroprusside-induced intracranial hypertension. JAMA. 1981;246:2679-2680.
61. Anile C, Zanghi F, Bracali A, et al. Sodium nitroprusside and intracranial pressure. Acta Neurochi (Wien). 1981;58:203-211. (Pubitemid 12238349)
62. Pasch T, Schulz V, Hoppelshäuser G. Nitroprusside-induced formation of cyanide and its detoxication with thiosulphate during deliberate hypotension. J Cardiovasc Pharmacol. 1983;5:77-85. (Pubitemid 13177955)
63. Cheung AT, Cruz-Shiavone GE, Meng QC, et al. Cardiopulmonary bypass, hemolysis, and nitroprusside-induced cyanide production. Anesth Analg. 2007;105:29-33.
64. Nakamura Y, Yasuda M, Fujimori H, et al. Cytotoxic effect of sodium nitroprusside on PC12 cells. Chemosphere. 1997;34:317-324. (Pubitemid 27077515)
65. Gobbel GT, Chan TY, Chan PH. Nitric oxide- and superoxidemediated toxicity in cerebral endothelial cells. J Pharmacol Exp Ther. 1997;282:1600-1607. (Pubitemid 27408346)
66. Rauhala P, Khaldi A, Mohanakumar KP, et al. Apparent role of hydroxyl radicals in oxidative brain injury induced by sodium nitroprusside. Free Radic Biol Med. 1998;24:1065-1073. (Pubitemid 28246719)
67. Niknahad H, O'Brien PJ. Involvement of nitric oxide in nitroprusside-induced hepatocyte cytotoxicity. Biochem Pharmacol. 1996;51:1031-1039. (Pubitemid 26104625)
68. Barsotti A, Di Napoli P, Taccardi AA, et al. MK-954 (losartan potassium) exerts endothelial protective effects against reperfusion injury: evidence of an e-NOS mRNA overexpression after global ischemia. Atherosclerosis. 2001;155:53-59. (Pubitemid 32167124)
69. Doerschug KC, Delsing AS, Schmidt GA, et al. Renin-angiotensin system activation correlates with microvascular dysfunction in a prospective cohort study of clinical sepsis. Crit Care. 2010;14:(R24):1-9.
70. Frohlich ED. Recent advances in hypertension, stroke, and cardiorenal disease. Curr Opin Cardiol. 2005;20:258-263. (Pubitemid 40896362)
71. Ferrari R, Guardigli G, Ceconi C. Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium. Cardiovasc Drugs Ther. 2010;24:331-339.
72. Re RN. Tissue renin angiotensin systems. Med Clin North Am. 2004;88:19-38. (Pubitemid 38160940)
73. Volpe M, Tocci G. Antihypertensive therapy and cerebrovascular protection. Curr Opin Nephrol Hypertens. 2006;15:498-504. (Pubitemid 44250739)
74. Gibney EM, Casebeer AW, Schooley LM, et al. Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: a national Veterans Administration study. Kidney Int. 2005;68:826-832. (Pubitemid 43323140)
75. Benedetto U, Sciarretta S, Roscitano A, et al. Preoperative Angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting. Ann Thorac Surg. 2008;86:1160-1165.
76. Pigott DW, Nagle C, Allman K, et al. Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements. Br J Anaesth. 1999;83:715-720. (Pubitemid 29502049)
77. Ryckwaert F, Colson P, Ribstein J, et al. Haemodynamic and renal effects of intravenous enalaprilat during coronary artery bypass graft surgery in patients with ischaemic heart dysfunction. Br J Anaesth. 2001;86:169-175. (Pubitemid 32103403)
78. Oh YJ, Lee JH, Nam SB, et al. Effects of chronic angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor treatments on neurohormonal levels and haemodynamics during cardiopulmonary bypass. Br J Anaesth. 2006; 97:792-798. (Pubitemid 44823663)
79. Kross RA, Ferri E, Leung D, et al. A comparative study between a calcium channel blocker (Nicardipine) and a combined alpha-betablocker (Labetalol) for the control of emergence hypertension during craniotomy for tumor surgery. Anesth Analg. 2000;91:904-909.
80. Murphy MB, Murray C, Shorten GD. Fenoldopam: a selective peripheral dopaminereceptor agonist for the treatment of severe hypertension. N Engl J Med. 2001;345:1548-1557. (Pubitemid 33144922)
81. Bodmann KF, Tröster S, Clemens R, et al. Hemodynamic profile of intravenous fenoldopam in patients with hypertensive crisis. Clin Investig. 1993;72:60-64. (Pubitemid 24002253)
82. Tumlin JA, Dunbar LM, Oparil S, et al. Fenoldopam, a dopamine agonist, for hypertensive emergency: a multicenter randomized trial Fenoldopam Study Group. Acad Emerg Med. 2000;7:653-662. (Pubitemid 30390491)
83. Munger MA, Rutherford WF, Anderson L, et al. Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension. Crit Care Med. 1990;18:502-504. (Pubitemid 20164872)
84. White WB, Radford MJ, Gonzalez FM, et al. Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam. J Am Coll Cardiol. 1988;11:1118-1123.
85. Goldberg ME, Cantillo J, Nemiroff MS, et al. Fenoldopam infusion for the treatment of postoperative hypertension. J Clin Anesth. 1993;5:386-391. (Pubitemid 23290101)
86. Shusterman NH, Elliott WJ, White WB. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function. Am J Med. 1993;95:161-168. (Pubitemid 23242709)
87. White WB, Halley SE. Comparative renal effects of intravenous administration of fenoldopam mesylate and sodium nitroprusside in patients with severe hypertension. Arch Intern Med. 1989;149:870-874. (Pubitemid 19133008)
88. Reisin E, Huth MM, Nguyen BP, et al. Intravenous fenoldopam versus sodium nitroprusside in patients with severe hypertension. Hypertension. 1990;15:(2 suppl): I59-I62.
89. Lund-Johansen P. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol. Drugs. 1984;28:(suppl 2):35-50.
90. Kanto J, Allonen H, Kleimola T, et al. Pharmacokinetics of labetalol in healthy volunteers. Int J Clin Pharmacol Ther Toxicol. 1981;19:41-44. (Pubitemid 11160578)
91. Goldberg ME, Clark S, Joseph J, et al. Nicardipine versus placebo for the treatment of postoperative hypertension. Am Heart J. 1990;119:(2 Pt 2):446-450. (Pubitemid 20048401)
92. Pearce CJ, Wallin JD. Labetalol and other agents that block both alpha- and betaadrenergic receptors. Cleve Clin J Med. 1994;61:59-69. (Pubitemid 24053928)
93. Wallin JD. Adrenoreceptors and renal function. J Clin Hypertens. 1985;1:171-178.
94. Marx PG, Reid DS. Labetalol infusion in acute myocardial infarct ion with systemic hypertension. Br J Clin Pharmacol. 1979;8(suppl 2):233S-238S. (Pubitemid 10180255)
95. Olsen KS, Svendsen LB, Larsen FS, et al. Effect of labetalol on cerebral blood flow, oxygen metabolism and autoregulation in healthy humans. Br J Anaesth. 1995;75:51-54.
96. Rosei EA, Trust PM, Brown JJ, et al. Letter: intravenous labetalol in severe hypertension. Lancet. 1975;2:1093-1094.
97. Cruise CJ, Skrobik Y, Webster RE, et al. Intravenous labetalol versus sodium nitroprusside for treatment of hypertension postcoronary bypass surgery. Anesthesiology. 1989;71:835-839. (Pubitemid 20005238)
98. Malsch E, Katonah J, Gratz I, et al. The effectiveness of labetalol in treating postoperative hypertension. Nurse Anesth. 1991;2:65-71.
99. Sladen RN, Klamerus KJ, Swafford MW, et al. Labetalol for the control of elevated blood pressure following coronary artery bypass grafting. J Cardiothorac Anesth. 1990;4:210-221. (Pubitemid 20153242)
100. Geniton DJ. A comparison of the hemodynamic effects of labetalol and sodiumnitroprusside in patients undergoing carotid endarterectomy. AANA J. 1990;58:281-287. (Pubitemid 20338673)
101. Leslie JB, Kalayjian RW, Sirgo MA, et al. Intravenous labetalol for treatment of postoperative hypertension. Anesthesiology. 1987;67:413-416. (Pubitemid 18077426)
102. Balser JR, Martinez EA, Winters BD, et al. Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology. 1998; 89:1052-1059. (Pubitemid 28516528)
103. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol. 1989;63: 925-929. (Pubitemid 19105127)
104. Stumpf JL. Drug therapy of hypertensive crises. Clin Pharm. 1988;7:582-591.
105. Smerling A, Gersony WM. Esmolol for severe hypertension following repair of aortic coarctation. Crit Care Med. 1990;18:1288-1290. (Pubitemid 20377785)
106. Gray RJ, Bateman TM, Czer LS, et al. Use of esmolol in hypertension after cardiac surgery. Am J Cardiol. 1985;56:49F-56F. (Pubitemid 16216801)
107. Gray RJ, Bateman TM, Czer LS, et al. Comparison of esmolol and nitroprusside for acute post-cardiac surgical hypertension. Am J Cardiol. 1987;59:887-891. (Pubitemid 17061308)
108. Muzzi DA, Black S, Losasso TJ, et al. Labetalol and esmolol in the control of hypertension after intracranial surgery. Anesth Analg. 1990;70:68-71. (Pubitemid 20039981)
109. Gray RJ. Managing critically ill patients with esmolol. An ultra shortacting betaadrenergic blocker. Chest. 1988;93:398-403.
110. Lowenthal DT, Porter RS, Saris SD, et al. Clinical pharmacology, pharmacodynamics and interactions with esmolol. Am J Cardiol. 1985;56:14F-18F. (Pubitemid 16216796)
111. Reynolds RD, Gorczynski RJ, Quon CY. Pharmacology and pharmacokinetics of esmolol. J Clin Pharmacol. 1986;26(suppl A):A3-A14. (Pubitemid 16097793)
112. Varon J, Marik PE. The diagnosis and management of hypertensive crises. Chest. 2000;118:214-227. (Pubitemid 30485512)
113. Turlapaty P, Vary R, Kaplan JA. Nicardipine, a new intravenous calcium antagonist: a review of its pharmacology, pharmacokinetics, and perioperative applications. J Cardiothorac Anesth. 1989;3:344-355. (Pubitemid 19150336)
114. Varon J. Efficacy and safety of intravenous nicardipine in the control of postoperative hypertension. IV Nicardipine Study Group. Chest. 1991;99:393-398.
115. Schillinger D. Nifedipine in hypertensive emergencies: a prospective study. J Emerg Med. 1987;5:463-473. (Pubitemid 18048622)
116. David D, Dubois C, Loria Y. Comparison of nicardipine and sodium nitroprusside in the treatment of paroxysmal hypertension following aortocoronary bypass surgery. J Cardiothorac Vasc Anesth. 1991;5:357-361.
117. Halpern NA, Goldberg M, Neely C, et al. Postoperative hypertension: a multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitroprusside. Crit Care Med. 1992;20:1637-1643.
118. Dorman T, Thompson DA, Breslow MJ, et al. Nicardipine versus nitroprusside for breakthrough hypertension following carotid endarterectomy. J Clin Anesth. 2001; 13:16-19. (Pubitemid 32208688)
119. Halpern NA, Sladen RN, Goldberg JS, et al. Nicardipine infusion for postoperative hypertension after surgery of the head and neck. Crit Care Med. 1990;18:950-955. (Pubitemid 20311997)
120. Vincent JL, Berlot G, Preiser JC, et al. Intravenous nicardipine in the treatment of postoperative arterial hypertension. J Cardiothorac Vasc Anesth. 1997;11:160-164.
121. Rodriguez G, Varon J. Clevidipine: a unique agent for the critical care practitioner. Crit Care Shock. 2006;9:9-15.
122. Bailey JM, Lu W, Levy JH, et al. Clevidipine in adult cardiac surgical patients: a dosefinding study. Anesthesiology. 2002;96:1086-1094.
123. http://www.dovepress.com/parenteral-clevidipine-for-the-acute-control-of- bloodpressurein- the-a3407.
124. Ericsson H, Fakt C, Jolin-Mellgård A, et al. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol. 1999;47:531-538. (Pubitemid 29199725)
125. Ericsson H, Tholander B, Regårdh CG. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999;8:29-37. (Pubitemid 29117266)
126. Nordlander M, Björkman JA, Regårdh CG, et al. Pharmacokinetics and hemodynamic effects of an ultrashort-acting calcium antagonist. Br J Anaesth. 1996;76(suppl 1):A24.
127. Kieler-Jensen N, Jolin-Mellgård A, Nordlander M, et al. Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesthesiol Scand. 2000;44:186-193. (Pubitemid 30090268)
128. Segawa D, Sjöquist PO, Wang QD, et al. Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part II. J Cardiovasc Pharmacol. 2002;40:339-345. (Pubitemid 34971350)
129. Segawa D, Sjöquist PO, Wang QD, et al. Calcium antagonist protects the myocardium from reperfusion injury by interfering with mechanisms directly related to reperfusion: an experimental study with the ultrashortacting calcium antagonist clevidipine. J Cardiovasc Pharmacol. 2000;36:338-343. (Pubitemid 30660464)
130. Stephens CT, Jandhyala BS. Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens. 2002;24:301-313. (Pubitemid 34602704)
131. Powroznyk AV, Vuylsteke A, Naughton C, et al. Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol. 2003;20:697-703. (Pubitemid 37047744)
132. Aronson S, Dyke CM, Kereiakes D, et al. Blood pressure control with clevidipine compared to nitroglycerin in the treatment of perioperative hypertension: primary results from the randomized ECLIPSE trial [abstract]. J Am Coll Cardiol. 2007;49 (9 suppl A):315A-419A.